Omni Bio Pharmaceutical’s recombinant Fc-AAT development program is targeted for advancement into clinical trials in 2015/2016
Nov 19, 2014
Omni Bio Announces Presentation of Phase 1/2 Clinical Data for AAT at American Heart Association Scientific Sessions
Nov 18, 2014
Omni Bio Successfully Completes Cell Line Optimization for Novel Recombinant Biologic
Read All News
Omni Bio is conducting research on a series of novel and highly competitive recombinant forms of AAT.
Omni Bio Pharmaceutical, Inc.181 W. Boardwalk, Suite 202Fort Collins, CO 80525(970) 237-5178 (Corporate & Investor Inquiries)
Copyright 2014 Omni Bio Pharmaceutical, Inc.